Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients

Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or abov...

Descripción completa

Detalles Bibliográficos
Autores: Negri, Clara E. [UNIFESP], Goncalves, Sarah S., Sousa, Ana Cristina P. [UNIFESP], Bergamasco, Maria Daniela [UNIFESP], Martino, Marines D. V., Queiroz-Telles, Flavio, Aquino, Valerio Rodrigues, Castro, Paulo de Tarso O., Hagen, Ferry, Meis, Jacques F., Colombo, Arnaldo L. [UNIFESP]
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:Brasil
Institución:Universidade Federal de São Paulo (UNIFESP)
Repositorio:Repositório Institucional da UNIFESP
Idioma:inglés
OAI Identifier:oai:repositorio.unifesp.br:11600/58281
Acceso en línea:http://dx.doi.org/10.1128/AAC.00608-17
https://repositorio.unifesp.br/handle/11600/58281
Access Level:acceso abierto
Palabra clave:A. fumigatus
invasive aspergillosis
triazole resistance
antifungal resistance
Brazil
Descripción
Sumario:Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.

Similares en LA Referencia